Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00522782 · ClinicalTrials.gov registry record · Phase 4

Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children

A Phase 4 study, sponsored by AAADRS Clinical Research Center.

Completed
Registry status
Phase 4
Development phase
16
Enrollment target

NCT00522782 is a Phase 4 study that has completed, run by AAADRS Clinical Research Center. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00522782, a Phase 4 study, has completed, sponsored by AAADRS Clinical Research Center.

COMPLETED
Registry status
Phase 4
Development phase
16 participants
Enrollment target

Study Summary

To study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath NO, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.

Interventions

  • DRUG Nebulized Budesonide
  • DEVICE Nitric Oxide Analyzer

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2007-08
Est. Completion 2009-01
Phase Phase 4

Sponsor

AAADRS Clinical Research Center

3 total trials

What the Registry Record Tells You About NCT00522782

The ClinicalTrials.gov registry entry for NCT00522782 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AAADRS Clinical Research Center, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Nebulized Budesonide is the first listed.

NCT00522782 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00522782 about?

NCT00522782 is a clinical study titled "Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children". To study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath NO, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.

What is the current status of trial NCT00522782?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2007-08. Estimated completion is 2009-01.

What interventions are being tested in trial NCT00522782?

The interventions under investigation include: Nebulized Budesonide (DRUG), Nitric Oxide Analyzer (DEVICE).

Who is sponsoring clinical trial NCT00522782?

This trial is sponsored by AAADRS Clinical Research Center, which has 3 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.